Key Highlights
- Revenue was USD 1.71 million against an estimate of USD 1.28 million.
- Loss per share was USD 0.04 against an estimate of a USD 0.05 loss.
- Net loss was USD 8.81 million, against USD 7.91 million a year earlier.
- Cash and marketable securities were USD 45.3 million at September 30.
Rani Therapeutics (NASDAQ:RANI) reported third quarter 2026 Revenue of USD 1.71 million, against an estimate of USD 1.28 million. The loss per share was USD 0.04, compared with an estimate of a USD 0.05 loss.
Net loss was USD 8.81 million, compared with USD 7.91 million in the third quarter of 2025, of which USD 1.08 million was attributable to the non-controlling interest, against USD 2.50 million. The loss from operations was USD 9.22 million, compared with USD 7.26 million.
Operating Expenses
Research and development expenses were USD 6.02 million, compared with USD 3.22 million. General and administrative expenses were USD 4.91 million, compared with USD 4.04 million, with the filing attributing the USD 0.9 million increase primarily to a USD 0.7 million increase in third-party services and USD 0.2 million of higher other expenses.
Total operating expenses were USD 10.93 million, against USD 7.26 million. Other income (expense), net, increased by USD 1.1 million, primarily from a USD 0.4 million increase in interest income on marketable securities and a USD 0.7 million decrease in interest expense.
Nine-Month Results
For the nine months ended September 30, 2026, net loss was USD 25.24 million, compared with USD 31.88 million, and the loss from operations was USD 26.39 million, compared with USD 29.78 million. Total operating expenses were USD 31.51 million, against USD 29.95 million.
Research and development expenses for the nine months were USD 16.20 million, against USD 15.30 million, and general and administrative expenses were USD 15.31 million, against USD 14.65 million.
Liquidity and Structure
As of September 30, 2026, cash, cash equivalents and marketable securities totaled USD 45.3 million, including cash and cash equivalents of USD 3.62 million and marketable securities of USD 41.67 million. The company believes this amount is sufficient to fund its operations through at least twelve months from the date its financial statements are issued.
The filing describes organizational transactions completed with the company's initial public offering in August 2021, which made the company the ultimate parent of Rani Therapeutics, LLC, and a registration rights agreement with continuing LLC owners that hold economic nonvoting Class A units.
The filing reports an accumulated Deficit of USD 154.7 million as of September 30, 2026, and states that the company expects to continue to incur losses for the foreseeable future, with net losses that may fluctuate significantly from period to period. It also lists the progress and focus of its current and future Clinical Trials in the United States and abroad among the topics covered by its forward-looking statements.
Rani Therapeutics Q3 2026 Earnings: Key Takeaways
Rani Therapeutics reported third quarter 2026 revenue of USD 1.71 million and a loss per share of USD 0.04. Net loss was USD 8.81 million, and cash, cash equivalents and marketable securities were USD 45.3 million.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...